We were in FDA's trial for MDMA - here's why it should NOT be approved to treat PTSD

We were in FDA's trial for MDMA - here's why it should NOT be approved to treat PTSD READ MORE: Ex-Navy SEAL slams FDA for psychedelic therapy setback By Cassidy Morrison Senior Health Reporter For Dailymail.Com Published: 17:32, 5 August 2024 | Updated: 17:32, 5 August 2024 e-mail View comments Trials looking at the health benefits of MDMA ignored patients' worsening suicidal tendencies, according to multiple people involved in the studies. Three volunteers with PTSD said they felt more depressed weeks into the trial and for weeks after it ended, an effect of taking the psychoactive drug, also known as ‘molly’.

Lykos Therapeutics, the company masterminding the push to legalize MDMA for post-traumatic stress disorder, is accused of bias in reporting trial results to show a positive effect on people's PTSD symptoms, pressuring people to report positive effects, and ignoring those who said their symptoms got worse. The ongoing trials have been plagued with allegations of sexual misconduct and of doctors overseeing the study of holding ‘underground’ MDMA sessions not sanctioned by the trial using the drugs illegally. Patients take a dose of the drug while under supervision.

Sessions with a therapist then help people to come to terms with their trauma MDMA raises levels of three feel-good neurotransmitters in the brain - serotonin, dopamine, and norepinephrine. When a person 'comes down' from the high from the drug, those neurotransmitter levels plummet, leaving a person .